Preclinical toxicology (subacute and acute) and efficacy of a new squalenoyl gemcitabine anticancer nanomedicine.
This study investigates 1) the anticancer efficacy of a new squalenoyl prodrug of gemcitabine (SQgem) in nanoassembly form compared with gemcitabine at equitoxic doses and 2) the subacute and acute preclinical toxicity of these compounds. The toxicity studies revealed that SQgem nanoassemblies, like gemcitabine, were toxic, and they led to dose-dependent mortality after daily i.v. injections for 1 week, irrespective of the route of administration. However, a 4- to 5-day spaced dosing schedule (injections on day 0, 4, 8, and 13) was proved to be safer in terms of weight loss and hematological and other toxicity. Using this spaced dosing schedule, SQgem nanoassemblies exhibited impressive anticancer activity in mice bearing L1210 leukemia because this treatment led to 75% long-term survivors. In contrast, at equitoxic doses, neither free gemcitabine nor cytarabine led to longterm survivors and all the mice of these groups died of the disease. Further toxicity studies performed at lethal doses by blood and serum analysis and organ weight determinations revealed that the hematological toxicity was the dose-limiting toxicity in both SQgem nanoassemblies and gemcitabine, whereas probable gastrointestinal toxicity was also associated with free gemcitabine. The SQgem nanoassemblies did not display hepatotoxicity, which is one of the clinically encountered toxicities of gemcitabine. To summarize, these preclinical studies demonstrated that the toxicological profile of new squalenoyl gemcitabine nanomedicine was not distinct from that of the parent gemcitabine, whereas it was much more potent than gemcitabine at equitoxic doses and cytarabine at clinically relevant doses. These data support the candidature of SQgem for clinical trials.
Reddy
L Harivardhan
LH
Université Paris-Sud XI, Faculté de Pharmacie, Unité Mixte de Recherche Centre National de la Recherche Scientifique 8612, Institut Fédératif de Recherche 141, 92296 Châtenay-Malabry Cedex, France.
Marque
Pierre-Emmanuel
PE
Dubernet
Catherine
C
Mouelhi
Sinda-Lepêtre
SL
Desmaële
Didier
D
Couvreur
Patrick
P
D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use* / Q000633:toxicity; D003561:Cytarabine / Q000627:therapeutic use; D003841:Deoxycytidine / Q000031:analogs & derivatives* / Q000737:chemistry / Q000627:therapeutic use / Q000633:toxicity; D004353:Drug Evaluation, Preclinical; D007938:Leukemia / Q000188:drug therapy*; D051379:Mice; D008811:Mice, Inbred DBA; D050997:Nanomedicine; D049329:Nanostructures / Q000627:therapeutic use* / Q000633:toxicity; D013185:Squalene / Q000737:chemistry* / Q000627:therapeutic use* / Q000633:toxicity; D016896:Treatment Outcome; D000093542:Gemcitabine
D000970:Antineoplastic Agents; D003561:Cytarabine; D003841:Deoxycytidine; D013185:Squalene; D000093542:Gemcitabine